Sign in to view content

ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy

Jeffrey S. Heier, MD

Video
Published 2022

Related

Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Updates from the Field
2024
Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2020
Nonneovascular Age Related Macular Degeneration and Fluid
David Sarraf, MD
Annual Meeting Talks
2020

Category: AMD-Non-Neovascular

See more